About
NOT
Ended--
Last price (USDT)
244.38K
24h total (USDT)
1.36M
Total vol (USDT)
2024-05-10 08:00:00 ~ 2024-05-16 11:30:00
Trading time (UTC+0)
2024-05-16 16:00:00
Delivery time (UTC+0)
Total supply102.45B
Resources
Introduction
Notcoin started as a viral Telegram game that onboarded many users into Web3 through a tap-to-earn mining mechanic.
Notcoin (NOT) at a Crossroads: Will the Price Rebound or Extend the Downside Risk?
Back to the list Notcoin (NOT) at a Crossroads: Will the Price Rebound or Extend the Downside Risk? thenewscrypto.com 9 m Notcoin has plunged over 3%, trading at $0.00037. $NOT’s daily trading volume has reached $8.23 million. The 3.24% loss has pulled the crypto assets back to their recent lows. With the red charts hovering across the market, the dominant asset, Bitcoin (BTC), has slipped to the $70K mark. Turning attention toward the altcoin sector, Notcoin ($NOT) has plunged by 3.5% in value over the last 24 hours. The asset’s highest and lowest trading level is noted between $0.0003687 and $0.0003891, respectively. At the time of writing, Notcoin traded within the $0.0003737 range. In addition, the daily trading volume of $NOT has dropped toward the $8.23 million mark, according to CMC data. With the brief bullish momentum, the Notcoin price might rise to test the key resistance at around $0.0003759. More gains could invite the golden cross to emerge, and the bulls would likely send the price to its former high above $0.0003781. If Notcoin bears reclaim the lost ground, the price could retrace instantly to the $0.0003715 support range. A continued correction on the downside triggers the formation of the death cross. Gradually, the asset’s price might fall deeply below $0.0003693. Will Notcoin’s Technical Indicators Turn Fully Bullish? Notcoin’s Moving Average Convergence Divergence line is slightly above the signal line, it likely displays an early bullish force. It is close to neutral, and the trend direction is not confirmed yet. If the MACD moves above, the bullish outlook gets stronger, and a reversal would erase the gains. $NOT chart (Source: TradingView) Moreover, the Chaikin Money Flow (CMF) indicator of $NOT located at 0.20 demonstrates strong buying pressure, with noticeable capital inflows. Accumulation is taking place, with the buyers supporting the price movement. It also reflects healthy market sentiment and sustained demand. The daily Relative Strength Index (RSI) at 51.30 indicates neutral to slightly bullish momentum. The buying pressure is slightly stronger than the selling pressure, with the Notcoin market relatively balanced, with no strong trend yet. Remarkably, a rise to 60 might strengthen the bullish momentum. Furthermore, the Bull Bear Power (BBP) reading stationed at 0.000002 suggests almost a neutral momentum for $NOT. As it is extremely close to zero, buyers and sellers are nearly balanced, with no clear dominance. Significantly, this positioning likely reflects a move sideways in the market. Latest news Will Polkadot price rebound as 21Shares launches first DOT ETF? crypto.news 12 m Ripple’s RLUSD and XRP Top Donation Charts u.today 13 m Why Bitcoin suffered a $110 billion wipeout despite its best week of Wall Street news in months coindesk.com 15 m 733 Billion SHIB Outflow: Binance's Shiba Inu Stockpile Dips 1.38% While Holding Massive 52.5 Trillion in Total Reserves u.today 20 m Bitcoin price falls under $70K again: Three key reasons cointelegraph.com 22 m Solana price deviates range-high resistance as capitulation risk grows crypto.news 22 m Top 5 Cryptocurrencies
What's Going On With Turbo Energy On Friday?
Turbo Energy, S.A. shares are surging on Friday, standing out in a broader market downturn. The company’s recent announcement about its innovative solutions to shield industrial operators from energy price shocks has captured investor attention, especially as global energy markets remain volatile. This development comes as the broader market indices, including the Nasdaq and S&P 500, are experiencing declines, highlighting the stock’s strong performance against a backdrop of general market pessimism. Details Turbo Energy’s SUNBOX Industry and SUNBOX Industry Max systems, which integrate large-scale battery storage with AI-driven software, are proving to be a game-changer. These systems not only enhance solar-plus-storage capabilities but also enable commercial and industrial operators to maintain robust operating margins despite fluctuating energy prices. This strategic protection is critical at a time when geopolitical tensions are causing significant volatility in oil and gas prices. The company’s focus on renewable electrification and its ability to mitigate the impact of energy price shocks on industrial earnings are pivotal. In particular, the company highlighted a $53 million industrial backlog, representing 366 MWh of projects and scheduled capacity across 10 manufacturing facilities in Spain. Mariano Soria, chief executive officer of Turbo Energy added, “Our AI-driven renewable electrification platform enables operators to proactively shield margins, manage fuel exposure, and strengthen financial resilience in dynamic market conditions. Intelligent storage is emerging as essential infrastructure for sustaining long-term industrial competitiveness.” With recent geopolitical developments triggering sharp movements in energy benchmarks, Turbo Energy’s solutions offer a tangible buffer, reinforcing the structural margin exposure that energy-intensive industries often face. Technical Analysis Over the past 12 months, Turbo Energy has seen a significant appreciation of 47% in its stock price. Currently, the stock is trading well above its key moving averages, which signals strong bullish momentum. Specifically, it is 293.9% above its 20-day SMA and 144.7% above its 100-day SMA. This performance is particularly notable given the broader market’s downturn, with major indices like the Nasdaq and S&P 500 showing declines today. The technical indicators further reinforce this positive outlook. The Relative Strength Index (RSI) is currently at 71.63, indicating that the stock is in the overbought territory, which could suggest a high level of investor interest and potential caution for incoming volatility. Additionally, the MACD is showing a bullish pattern, with the MACD line at 31 cents above the signal line at 8 cents, and a histogram value of 24 cents, highlighting the current upward momentum. Company Context Turbo Energy SA specializes in designing, developing, and distributing equipment for the generation, management, and storage of photovoltaic energy. The company sells inverters, batteries, and photovoltaic modules to installers and other distributors for residential consumers in Spain. Geographically it operates in Spain, Europe, and the rest of the world. TURB Price Action: Turbo Energy shares were up 14.90% at $3.47 at the time of publication on Friday. Photo via Shutterstock
KBW's Target Hike Suggests Arbor's Bottom May Be Nearer Than the "Strong Sell" Consensus Assumes
The core investment question for Arbor Realty TrustABR+0.40% is a classic game of expectations versus reality. The market's consensus is deeply bearish, assigning the stock a "Strong Sell" rating with a mean 12-month price target of $9.38. This reflects a wave of recent downgrades and price-target cuts from major firms, signaling that the worst-case scenarios are already priced in. Yet, within this gloomy outlook, a tactical divergence has emerged. KBW analyst Jade Rahmani maintains a "Sell" rating but recently raised his target price to $8.00. This move, while still negative, is a notable shift from his prior $7.50 target and suggests a subtle recalibration of near-term risk. This divergence is telling. It implies that while the overall trajectory remains down, some analysts see a potential for the stock to hold up better than the broad consensus expects. The stock's recent performance underscores how much pessimism has already been discounted. Over the past 120 days, shares have fallen -26.3%, trading down to a 52-week low of $7.11. This brutal decline means the market has already baked in severe headwinds. In this context, KBW's target hike looks less like a bullish call and more like a tactical adjustment to a lower baseline-a recognition that the stock may not fall as far as the average target suggests, even if it stays in a downtrend. The setup creates a clear expectation gap. The consensus "Strong Sell" implies further downside from current levels, but the stock's steep drop suggests that much of the bad news is already reflected. KBW's move to $8.00, therefore, could be interpreted as a signal that the worst of the sell-off may be over, or that the stock is now trading closer to its intrinsic value than the broad average target implies. For investors, the key is to weigh this tactical divergence against the overwhelming consensus. It hints that the stock might be less overvalued than the average target suggests, but it does not change the fundamental bearish narrative that dominates the analyst community. The Q4 Print: Reality vs. The Priced-In "Strong Sell" The fourth-quarter results delivered a mixed bag, but the key question is whether the operational reality met, exceeded, or fell short of the deeply pessimistic expectations already priced into the stock. The answer is nuanced: some metrics showed resilience, while others confirmed the persistent headwinds the bearish consensus anticipated. On the positive side, the company demonstrated a clear path to profitability. Distributable earnings came in at $0.22 per share, a solid beat against the prior quarter's $0.19. This sequential improvement is a tangible sign of operational progress. Furthermore, the agency business posted a standout quarter, with loan originations hitting $1.63 billion. More importantly, the agency servicing portfolio grew 8% to $36.2 billion, providing a predictable annuity income stream. This strength in the core, lower-risk business line is a critical counterweight to the broader challenges. Yet, the report also confirmed the heavy drag from legacy assets, a core reason for the "Strong Sell" rating. Total nonperforming assets remained high at approximately $1.1 billion. Management itself identified this as a major earnings headwind, estimating it causes an $80 million to $100 million annual pre-tax earnings drag. This is the reality that the market consensus has already discounted. The company also missed revenue expectations last quarter, a pattern that has persisted, as noted in the pre-earnings preview. This revenue weakness, driven by the runoff of the legacy portfolio, is the structural issue that the bearish view centers on. The bottom line is that the Q4 print validated the consensus view on the core problem while showing some pockets of strength. The beat on distributable earnings and the strong agency originations suggest the company is executing well in its core business. However, the high level of nonperforming assets and the persistent revenue miss confirm the underlying pressure that has led to the stock's steep decline. For investors, the expectation gap here is about the timing and magnitude of the resolution. The market has priced in a prolonged period of stress. The results show that stress is real, but the company is also generating the cash flow to manage it, which may explain KBW's tactical target hike. The stock's reaction will hinge on whether this operational reality is seen as a sign of stability or merely a slower burn than feared. The Guidance Reset Path: Runoff and Resolution as Catalysts The forward view hinges on a single, critical path: the resolution of legacy assets. Management has laid out a clear, if gradual, roadmap for this cleanup, which could serve as the catalyst for a future guidance reset. The key signal is the 11% sequential reduction in nonperforming assets, which brought the total to approximately $1.1 billion. More importantly, the company expects to generate $2 billion in balance sheet runoff in 2025, with a similar pace anticipated for the coming year. This runoff is the engine for reducing the $80 million to $100 million annual earnings drag that has plagued the stock. For the market, this is the tangible evidence that the worst of the legacy overhang is being systematically unwound, a process that could start to lift earnings visibility. Capital management actions in recent months signal confidence that the current price does not reflect this resolution potential. The company generated ~$90 million in liquidity by unwinding a CLO, a move that strengthens the balance sheet without issuing new equity. Simultaneously, it repurchased $20 million of stock at an average price of $7.40, a level that represents 64% of book value. This buyback, executed under a 10b5-1 plan, is a direct vote of confidence from management. It suggests the company believes its shares are trading below a meaningful discount to the underlying asset value, especially as the legacy portfolio shrinks. This sentiment is echoed by insider activity. The CEO, Ivan Kaufman, purchased 29,000 shares at $8.34 in November despite the wave of downgrades, raising his stake to 54,000 shares. Overall insider sentiment is positive, with recent purchases from other executives. This pattern of buying during a period of severe analyst pessimism is a classic indicator that those closest to the business see a disconnect between the current price and the asset resolution path ahead. The bottom line is that management is executing a deliberate plan to clean the balance sheet and return capital. The runoff target and the sequential reduction in problem assets provide a forward-looking narrative that could eventually narrow the expectation gap. The stock's steep decline has priced in prolonged stress. If the runoff and resolution proceed as guided, the market may eventually reassess the earnings trajectory, potentially leading to a guidance reset. For now, the actions signal that the worst is being managed, and the company is positioning itself to benefit from a cleaner, more predictable future. Catalysts and Risks: What Could Close the Gap? The path from today's expectation gap to a market sentiment shift hinges on a few clear catalysts and persistent risks. The primary catalyst is the continued execution of management's resolution plan. The sequential reduction in nonperforming assets and the steady $2 billion annual runoff are the tangible metrics that will validate the guidance reset narrative. If the company can consistently show progress in cleaning the balance sheet, it directly attacks the $80 million to $100 million annual earnings drag that has kept the stock depressed. This would be the operational proof that the worst of the legacy overhang is being unwound, potentially narrowing the gap between the current price and the asset value as the portfolio stabilizes. Yet, a key risk remains the structural pressure on the multifamily sector, which underpins a large part of the legacy portfolio. While the broader market shows resilience, with investment volume accelerating to a three-year high, the company's specific assets face headwinds. The sector's effective rent growth was sluggish, and the high level of nonperforming assets creates a vulnerability to further write-downs if property values or cash flows deteriorate. This risk could widen the expectation gap if management is forced to raise reserves or acknowledge slower resolution, reinforcing the bearish consensus. The next earnings report will be a critical test of both the catalyst and the risk. Investors must watch for two signals. First, whether revenue growth stabilizes after the significant miss last quarter, with the market now expecting a 20.3% year-on-year decline. Second, and more importantly, whether the company can consistently beat distributable earnings estimates. The Q4 beat to $0.22 per share was a positive sign, but a pattern of sequential improvement would be a stronger signal that operational resilience is translating into earnings power. A failure to meet or exceed these benchmarks would likely confirm the consensus view and keep the stock under pressure. In essence, the catalyst is the resolution path itself, while the risk is the underlying asset quality. The upcoming earnings report is the near-term event that will show which force is winning. For the expectation gap to close, the market needs to see the resolution catalyst gaining ground on the structural risks.
Critical minerals drive new commodity supercycle: Sprott
Governments and investors are increasingly treating critical materials such as copper and uranium as strategic assets, helping drive what Sprott says could be the early stages of a new commodity bull market. var rnd = window.rnd || Math.floor(Math.random() * 10e6); var pid472436 = window.pid472436 || rnd; var plc472436 = window.plc472436 || 0; var abkw = window.abkw || ''; var absrc = 'https://servedbyadbutler.com/adserve/;ID=181210;size=0x0;setID=472436;type=js;sw=' + screen.width + ';sh=' + screen.height + ';spr=' + window.devicePixelRatio + ';kw=' + abkw + ';pid=' + pid472436+ ';place=' + (plc472436++) + ';rnd=' + rnd + ';click=CLICK_MACRO_PLACEHOLDER'; document.write(' '); Commodity markets entered 2026 with renewed momentum as resource equities broke above long-term trading ranges after years of underrepresentation in global portfolios. According to a Sprott report released this week, the emerging cycle differs sharply from past booms, with structural forces such as deglobalization, fiscal expansion and rising geopolitical tensions reshaping demand for raw materials. Rather than mirroring the China-driven construction boom of 2000–2014 or the inflation-led rally of the 1970s, the emerging cycle is being powered by investment in electricity systems, digital infrastructure and energy security. Governments are increasingly prioritizing control over critical supply chains, pushing materials tied to electrification, defence and advanced infrastructure into strategic territory. Within the broader resource sector, performance has begun to diverge sharply. Materials tied directly to electrification, power generation and energy security are outperforming traditional bulk commodities that dominated earlier cycles. Source: Sprott report. The report highlights that the Sprott Critical Materials ETF (SETM) has significantly outperformed broader natural resource benchmarks since April 2025, underscoring growing investor focus on metals essential to modern infrastructure. Copper sits at the centre of this shift., helping tighten its supply-demand balance relative to construction-focused bulk commodities. According to Sprott, copper-focused producers have increasingly outperformed large diversified miners whose earnings remain more closely tied to iron ore and other bulks. Uranium over oil Energy markets show a similar divergence. Oil markets still face ample supply and a long-term decline in consumption intensity relative to global GDP. Uranium, by contrast, is entering the cycle with constrained supply and strengthening demand as countries revisit nuclear power. Sprott says the renewed interest in nuclear energy is driven primarily by energy security rather than environmental policy. Governments are extending reactor lifespans, planning new capacity and rebuilding long-term uranium contract coverage on the back of rising geopolitical tensions. Beyond copper and uranium, the firm sees favourable fundamentals for other critical materials including lithium, rare earth elements and silver. Lithium and rare earths are essential for batteries and high-efficiency motors, while silver benefits from both industrial demand and its role as a monetary metal. Source: Sprott report. The report argues that critical minerals are increasingly being valued not only by traditional supply-demand dynamics but also by their strategic importance to national security and technological infrastructure. Despite the shift, many resource allocations still emphasize broad exposure to sectors that dominated earlier cycles, such as chemicals, forest products and agriculture. Sprott says this lag in recognition is typical in the early stages of commodity bull markets. The firm expects investment in power generation, electricity grids, data centres and mineral supply chains to drive demand over a multi-year horizon. At the same time, long project lead times and a decade of underinvestment in new supply could keep markets tight. Targeted exposure to critical minerals may therefore offer stronger returns than broad commodity allocations, Sprott says. The firm highlights investment vehicles such as the Sprott Critical Materials ETF (NASDAQ: SETM), which focuses on companies deriving at least 50% of revenue or assets from critical materials, and the actively managed Sprott Active Metals & Miners ETF (NYSE: METL). While volatility remains likely, Sprott believes the structural forces reshaping the global economy could support sustained outperformance for select commodities and mining companies tied to electrification and energy security.
Is General Motors Company’s Stock Beating the Nasdaq’s Performance?
Overview of General Motors Company General Motors Company (GM), based in Detroit and established in 1908, stands as a major global automotive manufacturer. The company is renowned for designing, producing, and distributing vehicles and automotive components worldwide under iconic brands such as Chevrolet, Buick, GMC, and Cadillac. With a market capitalization of $73.3 billion, GM ranks among the top automakers in the United States by sales volume. The company maintains production sites in several countries and is actively advancing its efforts in electric vehicles, self-driving technology, and connected car services. GM's Market Position and Innovation GM is classified as a large-cap stock, given its market value exceeding $10 billion. The automaker is recognized for its blend of advanced engineering, cutting-edge technology, and a strong commitment to electrification. GM strives to deliver reliable, next-generation vehicles that offer a balance of performance, efficiency, and environmental sustainability for its customers. Latest Headlines from Barchart GM Stock Performance GM shares have declined by 10.3% from their 52-week peak of $87.62, reached on February 4. However, over the last three months, the stock has gained 4.4%, outperforming the Nasdaq Composite Index ($NASX), which fell by 3% during the same period. Year-to-date, GM’s stock has slipped 3.3%, but it has soared 73.8% over the past year. In comparison, the NASX has dropped 1.9% this year and increased 24.7% over the last twelve months. Since early July 2025, GM’s stock price has generally remained above its 50-day and 200-day moving averages, aside from a few brief dips. Financial Highlights and Outlook Over the past year, GM’s stock has experienced significant growth, supported by steady earnings and robust demand for its profitable SUVs and pickup trucks. In the fourth quarter of 2025, GM reported $45.3 billion in revenue—a 5.1% decrease year-over-year—while adjusted earnings per share climbed to $2.51 from $1.92, surpassing analyst expectations. The company further bolstered investor confidence by announcing a $6 billion share buyback program and providing a positive profit outlook for 2026, both of which contributed to the stock’s upward momentum. GM projects adjusted earnings per share between $11.00 and $13.00, suggesting further growth compared to the adjusted EPS of $10.60 achieved in 2025. Comparative Performance and Analyst Sentiment In contrast, Ford Motor Company (F), a key competitor, has lagged behind GM over the past year. Ford’s stock has fallen 2.4% in 2026, while delivering a 40.5% return over the previous year. Analysts on Wall Street remain largely positive about GM’s future. Among the 27 analysts covering the stock, the consensus rating is “Moderate Buy,” with an average price target of $92.24—representing a potential 17.4% upside from current levels.
Exclusive: Cyclops secures $8 million to develop stablecoin payment infrastructure for financial firms
Stablecoins Gain Traction Among Major Corporations Large international companies often face delays and restrictions due to traditional banking hours when processing payments. To overcome these limitations, many leading businesses—including airlines, hotel groups, stadium operators, and restaurant chains—are increasingly adopting stablecoins. These digital assets, powered by blockchain technology, enable immediate, 24/7 settlement of transactions. In response to this shift, new startups have emerged to support companies in this evolving environment. One such startup, Cyclops, is dedicated to helping payment firms accelerate their integration of stablecoin solutions. Cyclops Secures $8 Million in Funding On Wednesday, Cyclops revealed it had raised $8 million in a funding round led by Castle Island Ventures, F-Prime, and Shift4 Payments. The company did not disclose its current valuation. Building a Go-To Platform for Stablecoin Payments Alex Wilson, Cyclops' co-CEO and co-founder, explained, “Our mission is to become the primary platform that payment companies turn to when developing stablecoin-based products.” Wilson launched Cyclops alongside Pat Duffy and David Johnson. Real-World Adoption: Blade and Blue Origin Blade, a New York-based service that offers helicopter rides to airports, is among the companies utilizing Cyclops’ technology. Cyclops supplies the stablecoin infrastructure for Shift4, which processes Blade’s payments and is also an investor in Cyclops. Additionally, Blue Origin, the space travel company founded by Jeff Bezos, relies on both Shift4 and Cyclops for its payment operations. Founders’ Background and Motivation Before Cyclops, Wilson and Duffy co-founded The Giving Block in 2018, a platform that enables nonprofits to accept cryptocurrency donations. Shift4 acquired The Giving Block in 2022, after which Wilson and his co-founders spent over three years at Shift4, with Wilson leading crypto initiatives. Addressing Fragmentation in Crypto Payments The trio’s experience at Shift4 highlighted the challenges of working with multiple vendors—such as ZeroHash, Bridge, and BVNK—to build crypto payment solutions. Frustrated by this fragmented approach, they set out to create Cyclops as a comprehensive platform where payment companies could develop and manage their crypto services in one place. Business Model and Growth Plans Cyclops currently employs 20 people and earns revenue through transaction fees, though specific financial details remain confidential. Looking ahead, the company aims to expand its partnerships to include major payment processors like Fiserv, Adyen, and Global Payments. Cyclops is also interested in collaborating with payment networks such as Visa, Mastercard, and American Express. The Story Behind the Name When asked about the inspiration for the name Cyclops, Wilson shared that the team wanted to create a single, unified solution for payment companies, eliminating the need for multiple vendors. The founders also have an appreciation for Greek mythology, which influenced their choice. Clarifications Clarification: This article has been updated to specify that Cyclops’ goal is to assist payment companies in speeding up stablecoin adoption. A previous version suggested their infrastructure layer alone would facilitate this process. Clarification: The article now accurately states that both Duffy and Wilson co-founded The Giving Block.
Novo's 0.83% Gain on 162nd-Ranked Volume as Ireland Expansion and Eli Lilly Rivalry Signal Strategic Rebound
Market Snapshot Novo Nordisk (NVO) shares rose 0.83% on March 2, 2026, with a trading volume of $820 million, ranking 162nd in market activity that day. The modest gain contrasts with a broader decline in investor sentiment toward the company, as its stock has lost approximately 40% of its value over the past month. This follows a series of setbacks, including underwhelming clinical trial results for its next-generation CagriSema injection and heightened competition in the obesity drug market. Key Drivers Novo Nordisk’s recent investment of €432 million ($506 million) to expand its Athlone, Ireland, facility underscores its strategic pivot toward oral GLP-1 medications. The project, which began construction in early 2026 and is slated for completion by 2028, will significantly boost production capacity for Wegovy pills—a critical component of the company’s strategy to regain market share. The facility, which currently employs 260 staff, will produce Wegovy for international markets outside the U.S., where the drug launched in January 2026. Analysts note that the pill format addresses patient preferences for non-injectable treatments, a key differentiator in a market increasingly dominated by Eli Lilly’s Zepbound. The investment comes amid intensified competition and recent product challenges. A clinical trial revealed that Novo’s CagriSema injection delivered less weight loss than Lilly’s Zepbound, prompting Goldman Sachs to downgrade Novo’s stock to “neutral” from “buy.” This, combined with supply constraints for injectable semaglutide drugs (Ozempic and Wegovy), has eroded investor confidence. Compounding pharmacies have further pressured NovoNVO+0.83% by producing cheaper, legal versions of its drugs during shortages, a problem that persists despite increased manufacturing capacity. The company’s stock has since fallen to roughly a quarter of its mid-2024 peak. Ireland has emerged as a focal point in the pharma rivalry between Novo and LillyLLY-3.23%. While Novo expanded its Athlone site, Lilly announced an $800 million investment in its Cork facility in 2024 to produce active ingredients for weight-loss drugs. Novo’s previous decision to abandon a Dublin factory project and cut jobs at Athlone in 2024 highlighted its earlier strategic retrenchment. However, the latest investment signals a renewed commitment to Ireland as a manufacturing hub, leveraging the country’s status as a base for nine of the top ten global pharma firms. Enterprise Minister Peter Burke emphasized Ireland’s role in producing “innovative drugs,” reinforcing its position as a key player in the obesity care sector. Despite the investment, analysts remain cautious. Jyske Bank’s Henrik Hallengreen Laustsen described the Ireland project as a “sign of increasing focus on the oral space,” but noted that meeting global demand for Wegovy pills will remain challenging. The European Medicines Agency is expected to approve the drug by year-end, potentially expanding its reach. Meanwhile, Novo’s CEO, Mike Doustdar, emphasized that the company is not “throwing in the towel,” citing the Wegovy pill’s successful U.S. launch—described as “one of the strongest in pharmaceutical history”—as a foundation for future growth. The stock’s recent 0.83% gain suggests limited near-term optimism, but analysts argue the long-term viability of Novo’s strategy hinges on the success of Wegovy in pill form. With Eli LillyLLY-3.23% preparing to launch its oral weight-loss drug, orforglipron, in Q2 2026, the market will likely await concrete data on patient adoption and competitive dynamics before reassessing Novo’s prospects. For now, the Ireland investment reflects a strategic bet on oral therapies—a sector where Novo holds a first-mover advantage but faces mounting challenges from rivals.
3 Meme Coins To Watch In March 2026
March is shaping up to be explosive for select meme coins, with triple-digit monthly rallies and sharp weekly reversals reigniting speculative momentum. Technical indicators show aggressive capital inflows and strengthening buying pressure, hinting that some tokens may still have room to run. In line with the same, BeInCrypto has analysed three meme coins that the investors should keep an eye on in March. BUILDon (B) BUILDon price surged 42% over the past week, climbing to $0.189 and reversing its February losses. The meme coin regained momentum after prolonged weakness. This sharp rally reflects renewed investor interest and improved short-term sentiment within the broader crypto market. While the rest of the previous month was bleak for the meme coin, the past week proved to be a game-changer. The MFI verifies this rise as it shows that the indicator is climbing above the neutral mark. This is a sign of buying pressure taking control, which, if continued until the overbought threshold is hit, could push the B price past $0.203 and towards $0.275 to recover all of 2026 losses. BUILDon Price Analysis. Source: TradingView However, profit-taking remains a key risk. If holders begin selling into strength, upside could stall quickly. A reversal may push BUILDon toward Fibonacci supports at $0.162, $0.140, or $0.137. Such a decline would invalidate the bullish thesis and reintroduce downside pressure. Siren (SIREN) SIREN price has surged 271% over the past month, making it the top-performing meme coin. Despite the sharp rally, bullish momentum has not fully faded. Continued investor interest and elevated trading activity suggest the uptrend may still have room to extend. The Relative Strength Index shows renewed strength after a brief dip. RSI turning higher signals improving momentum. Trading at $0.298, SIREN could break above $0.386. Securing $0.465 as support would strengthen prospects for a move toward the $0.605 all-time high. SIREN Price Analysis. Source: TradingView However, profit-taking risk remains significant. If bullish momentum stalls or selling intensifies among its 42,000 holders, SIREN could decline toward $0.179. A deeper drop to $0.130 would invalidate the bullish thesis and erase much of the recent rally. Not in Employment, Education, or Training (NEET) NEET price has surged 223% over the past month, trading at $0.0205 at the time of writing. The meme coin continues to show buying pressure. The Money Flow Index remains above the neutral 50 mark, signaling sustained inflows and strengthening investor interest. If demand persists, NEET may not have reached its ceiling. A breakout above $0.0285 could extend gains toward $0.0336. Continued momentum may push the price beyond $0.0432, marking a recovery from prior losses and reinforcing the broader uptrend structure. NEET Price Analysis. Source: TradingView However, weakening bullish momentum would alter the outlook. Rising geopolitical risks could pressure speculative assets. A breakdown below $0.0166 may expose $0.0121 support. Such a decline would invalidate the bullish thesis and shift short-term momentum back to sellers.
SL Green and Jeff Sutton Sell 690 Madison Avenue
NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- SL Green Realty Corp. (NYSE:SLG), Manhattan’s largest office landlord, together with its joint venture partner, Jeff Sutton’s Wharton Properties, today announced that it has closed on the sale of 690 Madison Avenue for $54.5 million. “The sale of 690 Madison Avenue underscores the continued trend of significant demand for flagship locations occupied by high-end retail users along Manhattan’s finest retail corridors,” said Harrison Sitomer, Chief Investment Officer at SL Green. “We’re proud to have positioned the asset to an owner that shares our long-term vision.” 690 Madison Avenue is a five-story, 7,850-square-foot commercial building located at East 62 nd Street on the Upper East Side of Manhattan. The building is fully leased to Richemont’s Van Cleef & Arpels, a French luxury jewelry company. Gary Phillips and Will Silverman of Eastdil advised on the transaction. About SL Green Realty Corp. SL Green Realty Corp., Manhattan’s largest office landlord, is a fully integrated real estate investment trust, or REIT, that is focused primarily on acquiring, managing and maximizing the value of Manhattan commercial properties. As of December 31, 2025, SL Green held interests in 56 buildings totaling 31.4 million square feet. This included ownership interests in 28.0 million square feet of Manhattan buildings and 2.7 million square feet securing debt and preferred equity investments. SLG-A&D
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL (propranolol hydrochloride) Oral Solution
HEMANGEOL® is the only FDA-approved treatment for infantile hemangioma HEMANGEOL will be commercialized by Eton beginning May 1 st HEMANGEOL will be distributed through the company’s Eton Cares™ patient support program, which includes a $0 co-pay initiative, to broaden patient access. DEER PARK, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced it has in-licensed U.S. commercialization rights to HEMANGEOL ® oral solution from Pierre Fabre Medicament Sas (“Pierre Fabre”). HEMANGEOL is an Orphan Drug indicated for the treatment of proliferating infantile hemangioma requiring systemic therapy. “As the only treatment for infantile hemangiomas that require systemic therapy, HEMANGEOL is a critical medication and a strong fit with Eton’s orphan-focused commercial model. We look forward to expanding access to treatment by incorporating our Eton Cares patient support program, which includes our $0 commercial co-pay and best-in-class specialty distribution,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. “With this acquisition and the recent approval of DESMODA™ (desmopressin acetate), Eton has now achieved its long-held goal of ten commercial products,” Brynjelsen continued. “This major milestone reflects our continued progress toward building the largest rare disease portfolio in the United States.” Infantile hemangiomas are non-cancerous vascular tumors which typically appear in the first days or weeks of a newborn’s life. In severe cases, infantile hemangiomas can lead to serious complications including loss of vision, trouble breathing, or physical deformities, and require intervention with systemic therapy. Treatment with HEMANGEOL is typically initiated between ages five weeks to five months and continues for approximately six months. It is estimated that approximately 5,000-10,000 infants are treated with HEMANGEOL annually in the United States. The transaction is expected to be accretive to 2026 earnings and will be financed with the company’s cash on hand. Pierre Fabre will continue commercializing HEMANGEOL globally, and in the U.S. until April 30. Effective May 1, Eton will commercialize HEMANGEOL in the U.S. Eton plans to administer the Company’s best-in-class Eton Cares Program which provides prescription fulfillment, insurance benefits investigation, educational support, financial assistance for qualified patients, and other services designed to help patients access treatment. Eton Cares will offer co-pay assistance with $0 co-pay for qualifying patients. For more information about the product, patients and healthcare professionals can call Eton Pharmaceuticals at (847) 787-7361. Important Safety Information for HEMANGEOL Do not give HEMANGEOL to your child if your child: was born prematurely and has not reached the corrected age of 5 weeks weighs less than 4 ½ pounds is allergic to propranolol or any of the other ingredients in HEMANGEOL has asthma or a history of breathing problems has a heart problem, slow heart rate (less than 80 heart beats per minute), very low blood pressure is at risk for low blood sugar, for example is vomiting or unable to take feedings has high blood pressure caused by a tumor on the adrenal gland, called “pheochromocytoma” Tell your doctor about all of your child’s medical conditions, all of the medicines your child takes, and all of the medicines that you take if you are breastfeeding your child. HEMANGEOL can cause serious side effects, including: Low blood sugar (hypoglycemia), especially if your child is not taking feedings, or is vomiting. HEMANGEOL may make it more difficult to recognize the signs and symptoms of low blood sugar in your child. To help reduce the risk of low blood sugar with HEMANGEOL, give HEMANGEOL during or shortly after feeding your child. Feed your child regularly during treatment. Tell your doctor if your child has a poor appetite. If your child is not taking feedings, due to an illness or vomiting, do not give HEMANGEOL until your child is taking feedings normally again. If your child has any of the signs or symptoms of low blood sugar listed below during treatment with HEMANGEOL, stop giving your child HEMANGEOL and call your doctor or go to the nearest emergency room right away. Signs or symptoms of low blood sugar include: pale, blue or purple skin color, sweating, irritability, crying for no apparent reason, irregular or fast heartbeat, poor feeding, low body temperature, unusual sleepiness, seizures, breathing stops for short periods of time, and loss of consciousness If your child is conscious, give him/her a drink of a liquid containing sugar. Other serious side effects can include: New or worsening slow heart rate (bradycardia) or low blood pressure (hypotension). Breathing problems or wheezing. Stroke. HEMANGEOL may increase the risk of stroke in certain children who have severe problems with the blood vessels in their brain, particularly if your child has a large hemangioma that affects the face or head. Call your doctor or go to the nearest hospital emergency room if your child has: pale skin color, slow or uneven heartbeats, arms or legs feel cold, blue or purple skin color, or fainting. breathing problems or wheezing during treatment with HEMANGEOL. The most common side effects include: sleep problems, worsening respiratory tract infections, diarrhea, and vomiting. These are not all the possible side effects of HEMANGEOL. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Please see Full Prescribing Information and Medication Guide. About Eton Pharmaceuticals Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has ten commercial rare disease products: KHINDIVI TM , INCRELEX ® , ALKINDI SPRINKLE ® , DESMODA™, GALZIN ® , HEMANGEOL ® , PKU GOLIKE ® , Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four additional product candidates in late-stage development: Amglidia ® , ET-700, ET-800 and ZENEO ® hydrocortisone autoinjector. For more information, please visit our website at . Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton’s business strategy, Eton’s plans to develop and commercialize its product candidates, the safety and efficacy of Eton’s product candidates, Eton’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Pundit to XRP Investors: It’s Happening, Just As We Have Been Waiting for. Here’s the Latest
Financial markets often whisper before they roar. Subtle shifts in currencies or commodities can foreshadow broader liquidity tremors that ripple across global assets. This week, a sharp move in an unlikely corner of the market reignited debate among XRP investors who closely track macroeconomic signals. Crypto commentator Adam Rehberg brought fresh attention to the development on X, telling the XRP community that events may be unfolding just as anticipated. His remarks followed a 12.21% intraday surge in Brent crude oil priced in Japanese yen, which climbed to 12,390 JPY per barrel. Supporters of analyst Jake Claver’s macro thesis interpret the spike as an early indication that the yen carry trade may be entering a reversal phase. The Mechanics Behind a Potential Unwind The yen carry trade has fueled global liquidity for decades. Investors borrow cheaply in Japan and deploy that capital into higher-yielding global assets. However, when the Bank of Japan tightens monetary policy or signals sustained rate normalization, borrowing costs rise, and the yen strengthens. A stronger yen forces leveraged positions to close, which can trigger rapid asset sell-offs worldwide. XRP Fam! It’s happening, just as we have been waiting for. Reverse Carry Trade to unwind in the coming days? Jake’s theory unfolding as predicted. Jokes on those who have doubted him. Maybe his timeline was slightly off, but his research is proving true. — Adam Rehberg (@TheRealRehberg) March 1, 2026 Historical precedents support caution. During the 1998 Asian financial crisis, carry trade reversals coincided with significant equity drawdowns, with some markets falling between 20% and 30%. Although today’s financial system differs in structure and regulation, the core mechanism of forced deleveraging remains relevant. Jake Claver’s XRP Liquidity Thesis Jake Claver’s 2025 theory argues that a meaningful unwind could spark a liquidity crunch that pressures traditional markets while accelerating demand for efficient cross-border settlement tools. He positions XRP as a potential bridge asset in that scenario. Claver points to Ripple’s institutional infrastructure and strategic presence in Japan through SBI Holdings, which integrates XRP-related payment solutions within parts of its ecosystem. We are on X, follow us to connect with us :- — TimesTabloid (@TimesTabloid1) June 15, 2025 If volatility increases cross-border capital movement, institutions may prioritize speed and cost efficiency in settlements. XRP’s design enables near-instant transfers with low transaction costs, characteristics that could gain relevance during financial stress. Claver has publicly projected ambitious long-term targets, including a $750 scenario tied to systemic liquidity disruption and accelerated adoption. While such projections remain speculative and depend on widespread institutional uptake, they reflect his conviction in XRP’s macro positioning. Balancing Risk and Opportunity A carry trade unwind would likely create short-term turbulence across equities and digital assets. Liquidity contractions often pressure crypto markets before any structural benefits materialize. However, XRP differs from purely speculative tokens because it anchors its value proposition in remittances and institutional settlement efficiency. Rehberg’s message does not confirm a crisis. Instead, it highlights signals that align with a long-debated macro narrative. Whether the yen carry trade fully reverses remains uncertain. What remains certain is that global liquidity cycles increasingly intersect with digital asset markets, and XRP investors are watching closely as events unfold.
Mantle Reaches $1 Billion Milestone in Lending and Borrowing on Aave
Mantle has officially announced the new month’s beginning by achieving two big all-time highs in its decentralized finance (DeFi) ecosystem. By the end of March 1, 2026, the network had successfully passed the $1 billion mark for total lending and borrowing activity on the Aave platform alone. New month, new all-time highs. Actually, make that two: → Mantle crossed $1B in total lending and borrowing on @aave. → Mantle's DeFi TVL surged to $750M+, recording a 66% growth in 7 days. When MoMNTum is inevitable, DeFi is inevitable, and we proved it. pic.twitter.com/zZeUqKnunC — Mantle (@Mantle_Official) March 1, 2026 Moreover, Mantle has increased its total DeFi Total Value Locked (TVL) by over 750 million, which was one of the most rapid phases of growth in the history of the network. These milestones underscore the growing momentum of Mantle as it attempts to be the primary distribution layer between traditional financial and on-chain liquidity. Breaking the Billion-Dollar Barrier on Aave The biggest milestone in this announcement has been the total lending and borrowing volume of $1 billion realized in Aave. Aave is among the largest and most reputable decentralized lending protocols globally, and the capacity of Mantle to deliver this rate of volume via its network is a direct indication of institutional and retail trust. When a network is this active, it indicates that there is an extensive liquidity pool to be used by users who might be interested in earning interest on their assets or borrowing loans on their crypto as security. This one-billion-dollar success demonstrates that the platform is not simply a small participant in the space anymore but a big financial center that competes with some of the oldest players in the blockchain technology. Explosive Seven-Day Growth in DeFi Value Although achieving 1 billion on Aave is a huge achievement, the rate at which the ecosystem of Mantle is growing is also astounding. The Total Value Locked (TVL) of all the DeFi protocols at the platform increased by 66% in only the past 7 days. This increase took the total value to more than $750 million, indicating that investors are pouring their money into the platform’s ecosystem at an all-time high. New rewards, high-performance technology, and an increasing number of developers who create new applications are often stimulators of such expansion. To contextualize this growth, it’s challenging to achieve a 66% increase in a single week, suggesting that the platform has likely reached a critical juncture where its growth becomes inevitable. Linking Traditional Finance with Digital Markets The platform presents itself as the distribution layer bridging traditional finance (TradFi) to the liquidity on-chain. This mission will be vital in 2026 because more banks and large investment firms consider the possibility to transfer their assets to the blockchain to save money and become more transparent. Mantle is simplifying the flow of real-world money into the decentralized finance space by the infrastructure that acts as the bridge between these two worlds. This strategy has directly led to the recent increase in lending and borrowing since it offers the high-capacity environment that the high-capacity institutions would need. Since these institutions are still in the process of implementing blockchain technology, Mantle as a connector will surely become a necessary component of the financial backbone of the world. Future Outlook In prospect, the Mantle team feels that the apparent success is not the start of a significantly bigger trend. Mantle is establishing a new paradigm of what a modern blockchain network can be capable of by demonstrating that it can scale to support billions of dollars of volume and continue growing at an accelerated pace. The presence of liquidity in deep layers on applications such as Aave and a swiftly growing ecosystem of smaller DeFi initiatives is a flywheel effect in which liquidity brings in users, which brings in developers. As the network traverses into this new period of its growth, the focus will probably be on keeping this momentum and on continuing to record numbers in the coming months. The community is advised to remain vigilant as the Mantle keeps on conveying the fact that DeFi is not a one-time experiment but a necessary component of the future of money.
Notcoin (NOT) Price Prediction 2026, 2027 – 2030: Is NOT Set for a Gradual Comeback?
Story Highlights The live price of Notcoin (NOT) is $ 0.00035605 . Notcoin may trade between $0.020–$0.060 in 2026, with $0.20 possible by 2030 if support holds and adoption strengthens steadily. NOT remains in consolidation, with key support at $0.00030. A slow recovery could push prices toward $0.060 in 2026 and higher long term. With the first two months of 2026 already behind us, Notcoin’s price outlook is now being shaped by how the market behaves during this early phase of the year. After an intense period of volatility following its initial surge, NOT has settled into a quieter zone where price movement has slowed, and expectations have reset. This phase is common for tokens that experience early popularity. From a broader perspective, Notcoin’s long-term potential depends on whether it can maintain relevance beyond its early momentum. Community-driven tokens that survive their initial cycle often transition into slower, more structured recovery phases rather than quick rebounds. Early 2026 is therefore less about acceleration and more about foundation-building. Notcoin Price Today Cryptocurrency Notcoin Token NOT Price $0.0004 7.57% Market Cap $ 35,401,404.35 24h Volume $ 9,112,773.9282 Circulating Supply 99,429,405,866.9074 Total Supply 102,452,755,868.52 All-Time High $ 0.0290 on 02 June 2024 All-Time Low $ 0.0003 on 10 October 2025 Table of contents CoinPedia’s Notcoin Price Prediction Notcoin (NOT) Price March 2026 Outlook Notcoin (NOT) Price Prediction 2026 Notcoin Crypto Price Prediction 2026 – 2030 Notcoin (NOT) Price Prediction 2026 Notcoin Price Prediction 2027 Notcoin (NOT) Price Forecast 2028 Notcoin Crypto Price Prediction 2029 Notcoin (NOT) Price Prediction 2030 Notcoin Price Prediction 2031, 2032, 2033, 2040, 2050 Notcoin (NOT) Price Prediction: Market Analysis? FAQs CoinPedia’s Notcoin Price Prediction Coinpedia’s price prediction for Notcoin (NOT) depends on the current price structure and long-term participation potential. Notcoin could reach $0.0600 by the end of 2026 if it continues holding key support and regains intermediate resistance levels. Looking further ahead, steady adoption and favorable market conditions could support a move toward $0.20 by 2030. Year Potential Low ($) Potential Average ($) Potential High ($) 2026 0.020 0.038 0.060 Notcoin (NOT) Price March 2026 Outlook As March approaches, Notcoin’s price action remains defined by stability rather than expansion. The $0.00030–$0.00035 range has emerged as a key support zone, where selling pressure has consistently eased. As long as NOT holds above this area, the risk of deeper downside remains limited, and price is likely to continue moving sideways. On the upside, initial resistance is located near $0.00060, followed by a broader recovery zone between $0.0010 and $0.0015. These levels have capped price during previous attempts and will likely require time and steady participation to overcome. March is unlikely to deliver a sharp breakout. Instead, its importance lies in whether Notcoin can maintain its base and slowly build higher structure, setting the stage for recovery later in the year. Notcoin (NOT) Price Prediction 2026 The broader 2026 outlook for Notcoin focuses on whether the token can move from stabilization into a slow recovery phase. If market conditions improve and interest returns to community-driven projects, Notcoin could benefit from renewed participation. Tokens that endure early volatility often see their next phase unfold gradually, supported by consistency rather than speculation. From a price-structure perspective, reclaiming the $0.010–$0.015 range would signal that NOT has exited its long consolidation phase. Above this zone, historical resistance becomes thinner, allowing room for further upside. Under favorable market conditions, Notcoin price could reach around $0.0600 by the end of 2026. This move would represent a recovery from deeply discounted levels rather than a short-lived spike. A more conservative scenario would see NOT trading between $0.025 and $0.040 for much of the year before attempting higher levels. Notcoin Crypto Price Prediction 2026 – 2030 Year Potential Low ($) Potential Average ($ Potential High ($) 2026 0.020 0.038 0.060 2027 0.035 0.055 0.080 2028 0.060 0.095 0.140 2029 0.110 0.160 0.190 2030 0.150 0.180 0.200 Notcoin (NOT) Price Prediction 2026 In 2026, Notcoin price could project a low price of $0.020, an average price of $0.038, and a high of $0.060. Notcoin Price Prediction 2027 As per the Notcoin Price Prediction 2027, Notcoin may see a potential low price of $0.035. The potential high for Notcoin price in 2027 is estimated to reach $0.080. Notcoin (NOT) Price Forecast 2028 In 2028, Notcoin price is forecasted to potentially reach a low price of $0.060 and a high price of $0.140. Notcoin Crypto Price Prediction 2029 Thereafter, the Notcoin (Notcoin) price for the year 2029 could range between $0.110 and $0.190. Notcoin (NOT) Price Prediction 2030 Finally, in 2030, the price of Notcoin is predicted to remain steady and positive. It may trade between $0.150 and $0.200. Notcoin Price Prediction 2031, 2032, 2033, 2040, 2050 The long-term projection assumes Notcoin sustains relevance in enterprise blockchain use cases, with growth moderating over time as the asset matures. Year Potential Low ($) Potential Average ($) Potential High ($) 2031 0.18 0.25 0.32 2032 0.22 0.45 0.45 2033 0.30 0.80 0.65 2040 1.60 2.50 3.50 2050 5.00 8.50 12.00 Notcoin (NOT) Price Prediction: Market Analysis? Year 2026 2027 2030 Changelly $0.045 $0.065 $0.110 CoinCodex $0.050 $0.075 $0.150 WalletInvestor $0.060 $0.090 $0.180 Never Miss a Beat in the Crypto World! Stay ahead with breaking news, expert analysis, and real-time updates on the latest trends in Bitcoin, altcoins, DeFi, NFTs, and more. Subscribe to Price Prediction FAQs What is the Notcoin price prediction for 2026? Notcoin may trade between $0.020 and $0.060 in 2026, with average prices near $0.038 if it holds support and regains momentum. What is the price prediction for Notcoin in 2027? In 2027, Notcoin may range roughly from $0.035 at lows up to $0.080 at highs, reflecting gradual recovery potential. How much will Notcoin be worth in 2030? By 2030, Notcoin could reach around $0.150–$0.200 if adoption grows and market conditions remain supportive. Is now a good time to buy Notcoin? Buying Notcoin now may suit long-term holders if you believe in its future adoption, but volatility remains high with risk of sideways action. What long-term price outlook does Notcoin have? Long term, Notcoin’s value depends on adoption and relevance; strong recovery could see levels above $0.20 and beyond over years. Tags Price Prediction
Oddity Tech's Downturn: How a Revised Outlook Undermined Expectations of Sustained Expansion
Market Response: Oddity Tech's Earnings and the Shift in Sentiment Oddity Tech’s latest earnings release triggered a classic “sell the news” reaction. Despite surpassing expectations, the company’s warning signaled a dramatic shift in its growth outlook, undermining the optimism that had been reflected in its share price. For the fourth quarter, Oddity Tech reported earnings per share of $0.20, beating the consensus estimate of $0.14, and generated $152.73 million in revenue—a 23.8% increase from the previous year. This marked the eleventh straight quarter of revenue growth, capping off a record-setting year. While the headline numbers were strong and likely fueled the stock’s rally, the subsequent guidance reset created a significant disconnect between expectations and reality, erasing those gains. On February 25, shares plummeted by more than 48% after management revealed a major issue: an unprecedented disruption with its largest advertising partner, Meta Platforms. A change in Meta’s ad algorithm rerouted campaigns into less efficient auctions, causing customer acquisition costs to more than double. As a result, Oddity now anticipates first-quarter revenue to fall by about 30% compared to the prior year and has suspended its full-year 2026 outlook. The crux of the issue is clear: while investors had factored in continued growth and strong execution, they were blindsided by an operational crisis that threatens the company’s core user acquisition strategy. The stock’s sharp decline wasn’t about missing a quarterly target—it reflected a sudden and severe reset of the company’s growth prospects. The real gap was not between revenue and consensus, but between Oddity’s historical performance and the new reality of higher costs and stalled expansion. The Reset: From Growth Story to CAC Challenge This expectation gap was driven by more than just a revenue miss—it was the result of a sudden operational crisis that rendered Oddity’s main growth engine unprofitable. The root cause was an algorithmic mismatch with a key advertising partner, likely a major digital platform. This wasn’t a minor hiccup; the change funneled Oddity’s ad spend into inefficient auctions, doubling customer acquisition costs (CAC). This doubling of CAC is pivotal. It made initial purchases unprofitable, directly undermining Oddity’s user acquisition model. As CEO Oren Holtzman explained, these higher costs have severely limited the company’s ability to efficiently attract new users at scale—a process that had been successful for eight years. The market had counted on this reliable, scalable growth, but now the business model itself is in question. Management expects the most significant impact during the first half of 2026, projecting a roughly 30% drop in Q1 revenue. This is not a short-term setback, but a fundamental reset of the company’s growth trajectory. Oddity’s recovery plan aims for meaningful progress in the second quarter and a return to normalcy by the third or fourth quarter. In effect, the revised guidance translates the CAC crisis into a year of operational disruption before any rebound in growth can be expected. Analyst Reactions: A New Market Consensus Emerges The wave of analyst downgrades following the earnings report signals a wholesale reset of market expectations. The narrative has shifted from growth to crisis management. Jefferies and Citizens Jmp led the way with aggressive cuts. Jefferies slashed its price target by 72%—from $64 to $18—and downgraded the stock from “buy” to “hold” in a recent research note, acknowledging that the new trading baseline is around $14. Citizens Jmp also downgraded Oddity from “strong-buy” to “hold.” These moves indicate that analysts no longer expect a quick return to the company’s previous growth path. The revised price targets now range from a high of $64 to a low of $13, with the average settling near $31.73. This average represents a steep discount from pre-plunge levels above $45, reflecting expectations for a prolonged period of operational challenges before growth resumes. KeyCorp’s approach is noteworthy: it maintained an “overweight” rating but lowered its target to $30, suggesting that while long-term potential remains, near-term risks are now front and center. This split perspective captures the new reality—Oddity’s business model and long-term outlook are intact, but the immediate risks and CAC crisis have raised the bar for investors. In summary, analysts have shifted from a “buy the rumor” mentality to a “wait and see” stance. The downgrades and target reductions formally acknowledge that the expectation gap now includes a fundamental threat to Oddity’s user acquisition engine. Growth must now be demonstrated, not assumed. Navigating Forward: Catalysts and Risks in the New Landscape The stock’s new support level will depend on upcoming events that test Oddity’s recovery plan against the market’s drastically lowered expectations. The main catalyst is the first-quarter 2026 results in May, which will confirm the anticipated 30% revenue decline and reveal whether the advertising algorithm issue is being resolved. If results meet forecasts and show improvement in CAC, it would validate management’s timeline. A miss, however, could trigger further declines. The biggest risk is that the ad partner’s algorithm fix is delayed or incomplete. Management is targeting significant progress in Q2 and normalization in Q3 or Q4. If the problem persists, Oddity may face a longer period of unprofitable user acquisition, potentially forcing further cuts to growth investments or additional guidance reductions. The market has already priced in a year of disruption; any extension would widen the expectation gap once more. Another key milestone is the return of full-year guidance in Q2, which will set the new growth trajectory and test management’s credibility. Investors will closely examine the new outlook for signs of a return to pre-crisis growth rates. Given Oddity’s strong 2025 results and loyal customer base, the updated guidance must present a convincing path back to growth to support a recovery in valuation. At this point, the consensus is to wait and see. Analysts have lowered their targets and ratings, acknowledging the operational crisis. The stock’s future now depends on Oddity’s ability to execute its recovery plan and deliver the promised improvements. The narrative has shifted from growth to crisis management, and until the Q1 results and Q2 guidance provide clear evidence that the CAC crisis is easing, the stock remains vulnerable to further downside if progress stalls.
Evaluating the Strategic and Financial Consequences of the US-Israel Attack on Iran
Major Escalation in Iran Conflict: Coordinated Strikes and Regional Fallout On Saturday morning, a significant escalation unfolded in the ongoing dispute over Iran's nuclear program. The United States and Israel jointly carried out a series of military strikes, resulting in explosions across several Iranian cities, including Tehran and the religious center of Qom. Other targeted locations reportedly included Isfahan, Kermanshah, and Karaj, with some strikes occurring near the offices of Supreme Leader Ayatollah Ali Khamenei. President Donald Trump described the operation as "major combat operations" in Iran, highlighting the operation's scale and intent. The main goal of the strikes was to neutralize threats to Israel, specifically targeting missile launch sites and UAV facilities. This action is consistent with Israel's longstanding concerns about Iran's military capabilities in the region. The operation followed a substantial U.S. military buildup, including the deployment of the USS Gerald R. Ford, and came after months of tense negotiations over Iran's nuclear ambitions. While the Trump administration previously claimed to have destroyed Iran's nuclear infrastructure in June, later reviews indicated only partial effectiveness. The latest strikes seem to be a direct response to intelligence suggesting Iran is attempting to restore its nuclear program, with officials warning that Iran could soon have enough material for a nuclear weapon. The immediate aftermath has heightened the risk of rapid retaliation. Iran responded swiftly by closing its airspace and promising a "crushing response" to the attacks. Defense sources indicated that an Iranian counterstrike, possibly involving missile launches, could occur within hours. Israel has already begun preparing for possible reprisals, activating air raid sirens and readying defenses. The region now faces a period of extreme instability, with the potential for the conflict to widen just as it was beginning to recover from the recent Israel-Hamas war. Financial Markets and Economic Consequences The shockwaves from the U.S.-Israel operation have already begun to affect global markets, particularly in the energy sector and among regional financial assets. The immediate impact is a surge in geopolitical risk, with oil prices expected to rise sharply. The threat to a major oil-producing region, combined with the likelihood of Iranian retaliation, has created fears of supply disruptions. Analysts anticipate Brent crude could climb above $90 per barrel, and remain elevated until tensions ease. Investors should watch this price level closely, as prolonged volatility above this threshold could signal deeper market anxiety and spark inflationary pressures worldwide. Regional markets are also under strain. Israel's economy, already weakened by ongoing conflict, now faces direct military threats. The Tel Aviv 35 index and other local benchmarks are at risk of sharp declines as investors reassess the region's security. Even Gulf states, though not directly involved, may experience increased volatility and capital outflows as the perceived risk of doing business rises. The costs of military mobilization and heightened alert levels in Israel are likely to dampen business confidence and consumer activity. The financial burden of this operation is considerable. The strikes were preceded by the largest U.S. military deployment since the Iraq war, involving two aircraft carriers, several destroyers, and extensive support assets. Maintaining these forces, along with the potential for prolonged operations and additional air defense needs, will further strain the U.S. defense budget. This comes at a time when Congressional approval for military action is under scrutiny, with some lawmakers labeling the strikes as unauthorized acts of war. As a result, the financial repercussions include both immediate market turbulence and longer-term fiscal challenges. Paths Forward: De-escalation or Prolonged Conflict? The situation now stands at a crossroads: either tensions will ease, or the region will slide into a drawn-out conflict. The outcome depends on several key factors. Diplomatic Talks: The upcoming Iran-U.S. nuclear negotiations in Geneva, scheduled for Thursday, represent the last remaining diplomatic channel. The recent military action has put these talks in jeopardy. If they are canceled or delayed, it could signal the end of diplomatic efforts and leave military escalation as the only option. Military Objectives: The strikes were intended as a preemptive measure to eliminate threats to Israel, focusing on missile and UAV sites. However, the broad scope of the attacks, including strikes on cities like Qom and Isfahan, suggests a wider punitive intent. This increases the risk that Iran will respond with more than just defensive measures. Cycle of Retaliation: Iran's pledge for a "crushing response" is likely to translate into direct military action, possibly targeting U.S. forces or using allied groups such as the Houthis in Yemen. These proxies have previously disrupted shipping in the Red Sea and could be activated to escalate the conflict further, potentially turning a bilateral confrontation into a regional war. Ultimately, de-escalation will require a rapid and credible diplomatic effort, which has been severely undermined by the latest strikes. Without such an initiative, the region faces a cycle of ongoing retaliation, increasing the risk of a broader war with each exchange. Key Indicators for Investors For investors, the future direction of the crisis will be determined by a few critical signals and events: Oil Prices: The most immediate indicator is the price of Brent crude. Sustained levels above $90 per barrel would confirm that markets are pricing in a prolonged supply risk, likely due to fears of Iranian retaliation or a wider conflict. A drop below this level would suggest that the initial shock is subsiding and that de-escalation may be underway. Status of Geneva Talks: The fate of the scheduled nuclear negotiations will be a decisive diplomatic signal. Whether these talks proceed, are postponed, or are canceled will shape the outlook for further escalation or potential resolution. The recent strikes have cast doubt on the viability of negotiations, and their outcome will heavily influence market sentiment. Regional Equity Markets: The performance of indices such as the Tel Aviv 35 and the Dubai DFM will reflect investor confidence and the financial cost of instability. Significant declines would indicate heightened concerns about security and capital flight, with direct consequences for Israel's economy and Gulf financial centers. Monitoring these markets for signs of stabilization or further outflows will provide real-time insight into the economic impact of the crisis. In summary, the region stands at a critical juncture, with the potential for either a return to diplomacy or a slide into deeper conflict. Investors and policymakers alike must closely monitor these key developments to gauge the evolving risks and opportunities.
Diana Shipping: Assessing the Sector Rotation Case for a Dry Bulk Conviction Buy
The fourth-quarter report from Diana ShippingDSX+0.78% presents a classic institutional puzzle. On the surface, the numbers tell a story of resilience: the company beat EPS estimates by $0.03 per share, and full-year net income rose to $17.8 million. Yet the operational picture is more complex. Net income for the quarter fell to $1.7 million, a sharp drop from $8.3 million a year ago, and revenue missed estimates by nearly $4 million. More telling are the underlying trends: time charter revenue and adjusted EBITDA both declined year-over-year, pressured by vessel sales and drydocking. This disconnect is the signal. The headline EPS beat masks a challenging year, but it is a beat that was likely driven by one-time or non-operational factors, not core business strength. The real story is in the forward visibility. Management has secured 12 time charters covering 76% of 2026 ownership days at an average fixed rate of $17,670 per day. This contracted revenue provides a crucial floor for earnings, insulating the company from the volatility that plagued the industry's "two halves" market backdrop in 2025. For institutional investors, this setup creates a potential sector rotation opportunity. The operational weakness in Q4 is a lagging indicator, a reflection of past fleet adjustments. The forward charter coverage, however, is a leading indicator of stability. It transforms DianaDSX+0.78% from a pure cyclical play into a more predictable cash-flow generator, a quality factor that can command a higher risk premium in a portfolio. The recent institutional activity, with 38 institutional investors adding shares last quarter, suggests some smart money is already positioning for this visibility. The bottom line is that the current valuation may not fully price in this structural tailwind of contracted revenue, making a conviction buy in dry bulk a plausible overweight for risk-adjusted returns. Forward Visibility: The Foundation for a Quality Factor The institutional case for Diana Shipping hinges on a fundamental shift in risk profile. The company's strategy of locking in revenue provides a critical floor for cash flow, transforming it from a volatile cyclical into a more predictable quality factor. This forward visibility is the bedrock for improved financial risk and enhanced credit quality, key inputs for portfolio construction. Management has secured $153 million in contracted revenue for 2026, covering 76% of the year's ownership days at an average fixed rate of $17,670 per day. This coverage is diversified across vessel types, with fixed rates for Ultramax, Panamax, and Capesize vessels averaging ~$14,500 to $24,300 per day. The strategy explicitly prioritizes stability over exposure to spot volatility. However, this comes at a cost: the locked-in rates are well below the recent peak spot levels. For context, the Capesize index jumped to $44,673 per day in early December, and Jefferies forecasts rates could climb to $27,500 per day in 2026. Diana's contracted rates, therefore, represent a deliberate bet on steady cash flow rather than capturing the cyclical peak. This disciplined approach directly reduces financial risk. The contracted revenue provides a reliable cash flow stream that insulates the balance sheet from the extreme swings that characterized the market's "two halves" backdrop in 2025. It enhances credit quality by improving debt service coverage and liquidity predictability. For institutional capital allocators, this visibility justifies a higher risk premium. The stock becomes a more attractive candidate for portfolios seeking to overweight the sector, not for its spot rate exposure, but for its structural advantage in generating stable returns. The bottom line is that Diana's forward visibility is the quality factor that makes a conviction buy plausible. Capital Allocation and Strategic Uncertainty The company's recent capital allocation decisions have tightened its liquidity and introduced a material strategic uncertainty. In the quarter, Diana spent $103.5 million to acquire a 14.8% stake in Genco and used another $23 million for share repurchases, alongside declaring a $0.01 quarterly dividend. These moves consumed significant cash, reducing the balance sheet to $122.3 million in cash. This level of liquidity is a critical buffer, especially given the company's net debt of 51% of market value and its strategy of locking in revenue at rates well below recent cyclical peaks. The strategic risk now centers on the Genco deal. Diana's board has rejected the company's $20.60/share cash offer for Genco's remaining shares, refusing to engage in discussions. This creates a clear dead end for the consolidation thesis that was a key part of the investment narrative. The board's counter-suggestion to acquire Diana itself lacks financial detail, making it a non-starter for serious negotiation. For institutional investors, this rejection transforms a potential catalyst into a liability. The $103.5 million investment is now stranded, with no clear path to a premium exit or operational synergy realization. This uncertainty directly impacts the company's financial flexibility. With cash constrained and a major strategic initiative blocked, Diana's ability to pursue other fleet expansion or acquisition opportunities is diminished. More critically, it reduces the liquidity cushion available to weather a downturn in the dry bulk market, where the "two halves" volatility of 2025 remains a relevant risk. The capital allocation has thus created a trade-off: it secured a minority stake in a peer but at the cost of reduced financial agility and a stalled path to a controlling position. For a portfolio overweight in dry bulk, this introduces a layer of operational and execution risk that wasn't present before. Sector Tailwinds and Institutional Flow Dynamics The institutional case for Diana Shipping is being tested against a powerful sector tailwind. The broader dry bulk market, particularly the Capesize segment, is experiencing a fundamental supply-demand imbalance that is driving rates to cyclical peaks. Spot rates for Capesize vessels jumped 16% to $44,673 per day in early December, a surge of over 200% year-on-year. This momentum is not a fleeting event but a structural shift, as tonne-mile demand is up 8% through November, significantly outpacing fleet growth of just 2%. The result is a tight market for prompt tonnage, with brokers noting very tight ballasting tonnage for December dates. This fundamental strength, supported by long-haul trade flows and the looming ramp-up of Guinea's Simandou project, suggests the sector's recovery is durable, not a speculative rally. Yet, institutional sentiment toward Diana itself has been cautious, creating a potential mispricing. Despite the bullish sector backdrop, the company's own stock saw mixed activity in the fourth quarter. While 38 institutional investors added shares, a similar number, 30, reduced their positions. This divergence signals that smart money is not uniformly rotating into the sector. The stock's recent performance reflects the broader optimism, with shares climbing 54% over the past 120 days. However, the 52-week range of $1.27 to $2.65 underscores the volatility inherent in this cyclical trade. The stock's 54% run-up may already be pricing in much of the sector's near-term good news, leaving little margin for error if fundamentals falter. This dynamic sets up a classic sector rotation opportunity. The fundamentals are strong, driven by real tonnage tightness. But institutional flows into Diana are hesitant, likely due to the company's specific challenges: its forward visibility is built on locked-in rates well below current peaks, and its capital allocation has introduced strategic uncertainty. For a portfolio overweight in dry bulk, this creates a nuanced setup. The sector's tailwind is undeniable, but the conviction buy must be selective. Diana's case rests on its ability to generate stable cash flow from its contracted fleet, a quality factor that may be undervalued relative to its peers. The cautious institutional flow suggests the market is waiting for clearer proof of that stability, making it a potential entry point for those with a longer time horizon and a focus on risk-adjusted returns.
Mosaic's Q4: Is the Weakness Already Priced In?
The numbers were a clear disappointment. For its fourth quarter, The Mosaic CompanyMOS-- reported a GAAP net loss of about $519 million and adjusted earnings per share of 22 cents. That figure missed the consensus expectation of 48 cents. Revenue also fell short, coming in at roughly $2.97 billion. The market's immediate reaction was a 5.7% drop in the stock price, a move that now appears directly tied to this report. This sell-off comes on the heels of a recent sentiment shift. Just last week, RBC Capital lowered its price recommendation on Mosaic to $28, maintaining a Sector Perform rating. The firm cited a tough 2026 ahead, with phosphate margins under pressure and challenges in key markets like Brazil. The earnings report reinforced that caution, highlighting weak North American fertilizer demand and softer volumes as key drags on profitability. So, the core question for investors is whether this news was already priced in. The stock's decline suggests the market is re-pricing expectations for the year. Yet, the magnitude of the miss-both on the bottom line and the EPS beat-raises the stakes. It's one thing for a company to guide to a difficult year; it's another for it to report a significant loss and a wide earnings shortfall. The recent downgrade provided a warning, but the actual results may have forced a more aggressive reassessment of near-term fundamentals. The Demand Deterioration: Phosphate's 20% Shrink and Its Drivers The core weakness in Mosaic's business is starkly quantified in its Q4 shipments. The company's phosphate sales volumes at approximately 1.3 million tonnes represented a sharp decline from the prior-year quarter's 1.6 million tonnes. More precisely, the market conditions drove an overall North America phosphate market shipments... down approximately 20% year-over-year. This collapse hit phosphate hardest, while potash demand held up relatively better, with volumes remaining flat at 2.2 million tons. The drivers behind this deterioration are clear and fundamental. The report cites two primary factors: sustained pressure on grower economics and an early onset of winter weather that compressed the application window. The latter created a logistical squeeze, but the former is the deeper structural issue. The weakness was particularly acute for phosphate because it is lower relative affordability as compared to potash. In a year of tight budgets, farmers prioritized the more essential nutrient, leaving phosphate sales vulnerable to any seasonal disruption. This demand shock is the direct cause of the reported financial pain. The massive volume drop, coupled with a gross margin in the quarter was $17 per ton, down from $85 per ton, crushed profitability in the division. The company was forced to adjust its production plan in response to weaker demand, a move that likely added operational friction. The bottom line is that the Q4 results reflect a real, on-the-ground collapse in fertilizer consumption, not just a temporary blip. The market sentiment shift, as signaled by the RBC downgrade, was a reasonable anticipation of this pressure. The actual numbers confirm it was severe. The 2026 Outlook: Cost Savings vs. Capital Intensity and Working Capital The market's pessimism is now fully reflected in the stock price, but the 2026 outlook reveals a complex trade-off between aggressive cost control and significant capital needs. Management has laid out a clear path to navigate the headwinds, but the sheer scale of the required investments and working capital drag means the path to recovery will be bumpy. The positive lever is cost savings. MosaicMOS-- achieved $150 million in cost savings in 2025 and is targeting an additional $100 million in 2026. This includes a notable sequential improvement in phosphate conversion costs, which fell to $112 per ton in Q4. The company also points to a blended rock cost per ton of $97 in its Brazilian operations, the lowest since 2021. These efficiency gains are critical for protecting margins as the company ramps production back up, with guidance for at least 7 million tonnes of phosphate in 2026. Yet, this savings effort is being offset by a major capital and cash flow drain. The company is guiding to capital expenditures of around $1.5 billion in 2026, a significant increase from 2025. This spending is largely for necessary but temporary projects like waste disposal and tailings dams. More pressing is the working capital impact. In 2025, the company's working capital use reduced cash flow by $960 million, a major contributor to its net debt increase. While management expects a $300 million to $500 million working capital release in 2026 as inventory normalizes, that still leaves a substantial cash outflow. MOS Trend The bottom line is that despite these headwinds, the company's financial model is designed to hold. Management expects free cash flow to exceed the minimum dividend requirement after accounting for CapEx and other spending. This is the key metric for investors-it signals that the business can fund its operations and debt reduction without external financing, even in a tough year. The risk is that the capital intensity and working capital needs could pressure liquidity further in the near term, making the dividend and debt paydown targets more vulnerable if demand remains weak. The setup is one of cautious optimism. The market has priced in the demand collapse and margin pressure, but it may not yet fully appreciate the scale of the capital and cash flow challenges required to rebuild. The company's plan is to use cost savings to offset these pressures, but the execution will be tested. For now, the consensus view is that the worst is priced in, but the path to a stronger cash flow profile is clearly defined-and expensive. Catalysts and Risks: What Could Change the Sentiment The current market sentiment, which has priced in a difficult 2026, now hinges on a few critical forward-looking factors. The primary risk is the continuation of weak North American demand into the spring planting season. RBC Capital's view of a tough 2026 is grounded in the expectation that phosphate margins will stay under pressure from high input costs. The company's own guidance acknowledges this, with CEO Bruce Bodine noting that conditions were starting to improve as farmers prepared for spring, but the path to a full recovery is uncertain. Any further delay or weakness in the spring application window would validate the pessimistic outlook and likely pressure the stock further. On the flip side, the most significant positive catalyst would be a faster-than-expected recovery in Brazil's credit environment. The company's Brazilian operations, Mosaic Fertilizantes, faced severe headwinds in Q4, with intensifying credit constraints and an influx of lower-cost Chinese imports weighing heavily on demand and margins. A resolution to these credit issues could quickly boost global demand and improve profitability for that segment, providing a meaningful offset to North American weakness. Another layer of uncertainty comes from regulatory developments. The ongoing U.S. anti-dumping investigation into Chinese phosphate imports has the potential to tighten global supply. If the investigation leads to import restrictions, it could reduce the oversupply of lower-analysis products that have been pressuring prices and margins, particularly in markets like Brazil. This would be a supply-side tailwind that could support pricing and improve the fundamental outlook for phosphate producers. The bottom line is that sentiment is poised for a reversal based on these catalysts. The market has priced in the demand collapse and margin pressure, but it may not yet be fully accounting for the potential speed of a recovery in key markets or the impact of regulatory changes. The risk/reward now depends on which of these forces-continued domestic weakness, a Brazilian turnaround, or a supply-side tightening-gains momentum first.
Aave Crosses $1 Trillion In Loans — No Bank Required
It started as an idea. Now it processes more lending volume than most people will ever see in a lifetime. Aave, the decentralized finance protocol that lets users borrow and deposit crypto without going through a traditional bank, has crossed $1 trillion in total cumulative lending — a milestone that has never been reached by any other protocol in the DeFi industry. Related Reading Is Bitcoin The Poor Man’s Hedge Against Inflation? Coinbase CEO Thinks So 1 day ago From A 2017 Startup To A Trillion-Dollar Lending Machine Aave was not always called Aave. Its founder, Stani Kulechov, first launched the platform under the name ETHLend in November 2017 before rebranding it in September 2018. What began as a small peer-to-peer lending experiment on the Ethereum blockchain has grown into the dominant force in decentralized lending, with over $27 billion in total user funds currently secured on the platform. var rnd = window.rnd || Math.floor(Math.random()*10e6); var pid607465 = window.pid607465 || rnd; var plc607465 = window.plc607465 || 0; var abkw = window.abkw || ''; var absrc = 'https://servedbyadbutler.com/adserve/;ID=172179;size=0x0;setID=607465;type=js;sw='+screen.width+';sh='+screen.height+';spr='+window.devicePixelRatio+';kw='+abkw+';pid='+pid607465+';place='+(plc607465++)+';rnd='+rnd+';click=CLICK_MACRO_PLACEHOLDER'; document.write(' '); if (!window.AdButler){(function(){var s = document.createElement("script"); s.async = true; s.type = "text/javascript";s.src = "https://servedbyadbutler.com/app.js";var n = document.getElementsByTagName("script")[0]; n.parentNode.insertBefore(s, n);}());} var AdButler = AdButler || {}; AdButler.ads = AdButler.ads || []; var abkw = window.abkw || ""; var plc366606 = window.plc366606 || 0; (function(){ var divs = document.querySelectorAll(".plc366606:not([id])"); var div = divs[divs.length-1]; div.id = "placement_366606_"+plc366606; AdButler.ads.push({handler: function(opt){ AdButler.register(172179, 366606, [728,90], "placement_366606_"+opt.place, opt); }, opt: { place: plc366606++, keywords: abkw, domain: "servedbyadbutler.com", click:"CLICK_MACRO_PLACEHOLDER" }}); })(); Aave crossed $1 trillion all-time loans. A first in DeFi history. pic.twitter.com/9zMKhtGq6R — Aave (@aave) February 25, 2026 Over the past 30 days alone, Aave generated more than $83 million in fees — nearly four times more than its nearest competitor, Morpho. Other well-known lending platforms including JustLend, SparkLend, Maple, and Compound Finance each hold over $1 billion in total value locked, but none come close to matching Aave’s scale. “A decade ago, DeFi and Aave didn’t exist. They were just ideas. Today, Aave stands as the backbone of onchain lending, powering a new financial system that is open, global, and unstoppable,” Kulechov said in a post on X following the announcement. var rnd = window.rnd || Math.floor(Math.random()*10e6); var pid607472 = window.pid607472 || rnd; var plc607472 = window.plc607472 || 0; var abkw = window.abkw || ''; var absrc = 'https://servedbyadbutler.com/adserve/;ID=172179;size=0x0;setID=607472;type=js;sw='+screen.width+';sh='+screen.height+';spr='+window.devicePixelRatio+';kw='+abkw+';pid='+pid607472+';place='+(plc607472++)+';rnd='+rnd+';click=CLICK_MACRO_PLACEHOLDER'; document.write(' '); if (!window.AdButler){(function(){var s = document.createElement("script"); s.async = true; s.type = "text/javascript";s.src = "https://servedbyadbutler.com/app.js";var n = document.getElementsByTagName("script")[0]; n.parentNode.insertBefore(s, n);}());} var AdButler = AdButler || {}; AdButler.ads = AdButler.ads || []; var abkw = window.abkw || ""; var plc452518 = window.plc452518 || 0; (function(){ var divs = document.querySelectorAll(".plc452518:not([id])"); var div = divs[divs.length-1]; div.id = "placement_452518_"+plc452518; AdButler.ads.push({handler: function(opt){ AdButler.register(172179, 452518, [728,90], "placement_452518_"+opt.place, opt); }, opt: { place: plc452518++, keywords: abkw, domain: "servedbyadbutler.com", click:"CLICK_MACRO_PLACEHOLDER" }}); })(); AAVEUSDT now trading at $115. Chart: His longer-term ambitions are even bigger. Kulechov has said he wants Aave to become the largest and most efficient liquidity network on the planet — one that banks, builders, and financial technology companies connect to by default. Big Finance Names Are Already At The Table Aave is no longer just for crypto enthusiasts. In August last year, Aave Labs launched a new product called Aave Horizon, a lending market built on Ethereum and designed specifically for traditional financial institutions. Related Reading Peter Schiff Says Bitcoin Has Never Beaten Gold Since 2021 1 day ago The idea is to allow established finance firms to borrow stablecoins using real-world assets as collateral. According to reports, VanEck, WisdomTree, and Securitize were among the first major institutions to participate in the offering — a sign that the gap between conventional finance and decentralized protocols is narrowing. var rnd = window.rnd || Math.floor(Math.random()*10e6); var pid607473 = window.pid607473 || rnd; var plc607473 = window.plc607473 || 0; var abkw = window.abkw || ''; var absrc = 'https://servedbyadbutler.com/adserve/;ID=172179;size=0x0;setID=607473;type=js;sw='+screen.width+';sh='+screen.height+';spr='+window.devicePixelRatio+';kw='+abkw+';pid='+pid607473+';place='+(plc607473++)+';rnd='+rnd+';click=CLICK_MACRO_PLACEHOLDER'; document.write(' '); if (!window.AdButler){(function(){var s = document.createElement("script"); s.async = true; s.type = "text/javascript";s.src = 'https://servedbyadbutler.com/app.js';var n = document.getElementsByTagName("script")[0]; n.parentNode.insertBefore(s, n);}());} var AdButler = AdButler || {}; AdButler.ads = AdButler.ads || []; var abkw = window.abkw || ''; var plc452519 = window.plc452519 || 0; (function(){ var divs = document.querySelectorAll(".plc452519:not([id])"); var div = divs[divs.length-1]; div.id = "placement_452519_"+plc452519; AdButler.ads.push({handler: function(opt){ AdButler.register(172179, 452519, [728,90], 'placement_452519_'+opt.place, opt); }, opt: { place: plc452519++, keywords: abkw, domain: 'servedbyadbutler.com', click:'CLICK_MACRO_PLACEHOLDER' }}); })(); Kulechov has also been vocal about what he sees as the next big opportunity for DeFi lending. Reports say he believes that tokenizing what he calls “abundance assets” — things like solar energy infrastructure, battery storage systems, and robotics used in labor — could open an entirely new category of collateral for decentralized lending. He expects those types of assets to be worth a combined $50 trillion by 2050. Featured image from BTCCard, chart from TradingView
Hecla Mining Surges 5.28% on $480M Volume, Climbs to 284th in Daily Trading Activity
Market Snapshot Hecla Mining (HL) surged 5.28% on February 26, 2026, with a trading volume of $0.48 billion, ranking 284th in market activity for the day. The stock’s performance followed a strong earnings report and operational updates, reflecting renewed investor confidence in the silver producer. Key Drivers The upward trajectory of HeclaHL+5.28% Mining’s stock was primarily fueled by its Q3 2025 financial and operational results, which significantly exceeded expectations. The company reported EPS of $0.15, surpassing forecasts by 66.67%, and revenue of $410 million, 49.13% above estimated figures. This outperformance translated into a 14.54% price surge to $13.72 post-earnings, signaling robust demand for the company’s output. Hecla also highlighted record revenue and net income of $101 million, alongside a dramatic reduction in net leverage from 1.8x to 0.3x, underscoring improved financial stability. All four of its producing assets generated positive free cash flow, with consolidated free cash flow reaching $90 million and operating cash flow at $148 million. These metrics reinforced the company’s transition from a cash-constrained operator to a financially flexible entity, as noted by CEO Rob Krcmarov. Operational momentum further bolstered the stock’s performance. Silver production increased 2% quarter-over-quarter, while exploration guidance for 2026—allocating 2-5% of revenue to exploration—hinted at future growth potential. Keno Hill’s anticipated commercial production in 2027 and nameplate throughput by 2028 added long-term catalysts. Analysts have taken notice: H.C. Wainwright maintained a “Buy” rating with a $36.5 price target (56.59% upside), while BMO Capital and Canaccord Genuity retained “Hold” and “Sell” designations, respectively. Despite mixed sentiment, the highest price targets (e.g., $36.5) suggest optimism about Hecla’s ability to capitalize on favorable metal prices and operational efficiency. The broader market context also played a role. Silver prices have historically been volatile, and Hecla’s ability to generate consistent cash flow amid production gains positioned it to benefit from potential price increases. Additionally, the company’s debt reduction—from 1.8x to 0.3x—reduced financial risk, making it a more attractive proposition in a sector often sensitive to cyclical commodity swings. This deleveraging aligns with industry trends, as miners prioritize balance sheet strength to fund exploration and capitalize on market opportunities. Looking ahead, Hecla’s strategic focus on exploration and asset development could drive further gains. The Keno Hill project, expected to reach commercial production in 2027, represents a key growth avenue. Meanwhile, the company’s emphasis on free cash flow generation—achieved through cost controls and operational efficiency—provides flexibility to reinvest in high-potential projects or return capital to shareholders. These factors, combined with a management team highlighting “rapid transformation” in favorable metal price environments, have positioned Hecla as a compelling play in the silver sector. In contrast, Maple Gold Mines’ recent drilling results, though impressive, did not directly impact Hecla’s stock. However, the broader gold and silver mining sector’s exploration successes and funding updates indirectly reinforced investor appetite for junior miners with strong operational and financial metrics. Hecla’s combination of immediate cash flow, reduced leverage, and future growth projects aligns with these sector dynamics, making its recent outperformance both justified and sustainable. The stock’s 5.28% gain on February 26 reflects a confluence of near-term execution, strategic clarity, and favorable analyst sentiment. While mixed price targets and some downgrades (e.g., Roth/MKM’s “Sell” rating) highlight risks, the company’s operational and financial improvements have clearly resonated with investors. As Hecla continues to execute its 2026 guidance and advance Keno Hill, its stock remains poised to benefit from continued momentum in the precious metals space.
Eli Lilly's New Oral Weight Loss Drug Outperforms Semaglutide, Eyes Potential US Approval In Q2
Eli Lilly and Co. (NYSE:LLY) shares are down on Thursday. The company announced promising results for its oral GLP-1 medication, orforglipron. On Thursday, the Zepbound maker shared detailed results from ACHIEVE-3, the first head-to-head Phase 3 trial evaluating orforglipron, an oral GLP-1, compared with Novo Nordisk A/S’ (NYSE:NVO) oral semaglutide in adults with type 2 diabetes inadequately controlled with metformin. The 52-week trial enrolled 1,698 participants. Lilly’s Oral Drug Outperforms Novo Nordisk’s Drug In ACHIEVE-3, orforglipron outperformed oral semaglutide across the primary and all key secondary endpoints, delivering significantly greater improvements in A1C (blood sugar) and weight. In the latest news, Eli Lilly reported that orforglipron 36 mg significantly outperformed oral semaglutide 14 mg in a Phase 3 trial, achieving a 2.2% reduction in A1C compared to 1.4% for the latter. Additionally, participants taking orforglipron lost an average of 19.7 lbs (9.2%), which is 73.6% greater weight loss than those on semaglutide. The company has submitted orforglipron for regulatory approval in over 40 countries, with a potential U.S. decision for obesity treatment expected in the second quarter of 2026. On Monday, Novo Nordisk released headline data from its REDEFINE 4, an open-label phase 3 trial from the global REDEFINE clinical trial program. The trial did not achieve its primary endpoint of demonstrating non-inferiority on weight loss for CagriSema compared to Eli Lilly’s tirzepatide after 84 weeks. The broader market experienced declines on Thursday, with the S&P 500 down 1.08% and the Nasdaq slipping 1.80%. Eli Lilly’s drop comes along with broader market weakness, suggesting that the positive news surrounding orforglipron may be driving investor interest independently of market trends. Technical Analysis Currently, the stock is trading 5.2% below its 20-day simple moving average (SMA) and 8.4% below its 100-day SMA, indicating some short-term weakness. Over the past 12 months, shares have increased approximately 65%, and they are currently positioned closer to their 52-week highs than lows. The RSI is at 50.00, which is considered neutral territory, indicating no strong momentum in either direction. Meanwhile, MACD is at 0.10, below its signal line at 0.15, suggesting bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum. Key Resistance: $1,100.00 Key Support: $950.00 LLY Price Action: Eli Lilly shares were down 1.97% at $1008.53 at the time of publication on Thursday. Image Via Shutterstock
Filled orders
Delivery scenarios